9th Annual NC Triangle Research Pulmonary Hypertension Symposium
The field of pulmonary arterial hypertension is a rapidly developing one, with multiple new treatments introduced in the last two decades. This has created a steep learning curve for pulmonologists and cardiologists treating this disease, as well as primary care physicians who must remain mindful to consider the diagnosis in their patients. This dynamic state of the field serves to perpetuate a gap in regard to the knowledge of appropriate diagnostic procedures, proper treatment choices, and timing of advancement of care to pulmonary hypertension specialty centers. It is imperative that those treating this specialized disease have a thoroughly grounded knowledge of the appropriate work up, treatment, and care of the pulmonary arterial hypertension (PAH) patient.
This program is designed to meet the continuing education needs of pulmonologists, cardiologists, and other allied health professionals involved in the treatment of pulmonary hypertension.
Advanced Practice Nurses
Allied Health Professional
At the conclusion of this activity, participants should be able to:
- Describe the classification of and proper diagnostic approach to pulmonary hypertension, according to the Fifth World Symposium and other recent consensus statements from experts in the field.
- Recognize and distinguish similar disease processes that may or may not respond to PAH specific therapy, including chronic thromboembolic pulmonary hypertension, Group 3 pulmonary hypertension, pulmonary veno-occlusive disease and others.
- Identify appropriate treatment choices based on available evidence, as well as understand what specific emerging therapies are currently under investigation for PAH.
- Recognize when treatment responses are suboptimal, how to properly assess prognosis and determine risk and outcomes, such that timing of referral to a specialty center is appropriate.
- Describe the evolution of PAH diagnosis and therapies from a historical perspective as well as potential future diagnostic and treatment modalities.
- Recognize important non-pharmacologic aspects of PH patient care, including the psychosocial impact of the disease as well as a current understanding of the genetics of PAH.
H. James Ford, MD
Terry Fortin, MD
Lisa Rose-Jones, MD
Barbara LeVarge, MD
Victor Test, MD
Talal Dahhan, MD
John Haney, MD
Allyson Rupp, MSW, LCSW
Victor Tapson, MD
Eric Austin, MD
Richard Krasuski, MD
Lynne Koweek, MD
Sudarshan Rajagopal, MD
H. James Ford, MD
In support of improving patient care, Duke University Health System Department of Clinical Education & Professional Development is accredited by the American Nurses Credentialing Center (ANCC), the Accreditation Council for Pharmacy Education (ACPE), and the Accreditation Council for Continuing Medical Education (ACCME), to provide continuing education for the health care team.
Physicians: Duke University Health System Department of Clinical Education and Professional Development designates this live activity for a maximum of 6.25 AMA PRA Category 1 Credit(s)TM. Physicians should claim only credit commensurate with the extent of their participation in the activity.
Nursing: Duke University Health System Department of Clinical Education and Professional Development designates this activity for up to 6.25 credit hours for nurses. Nurses should claim only credit commensurate with the extent of their participation in this activity.
Pharmacists: Duke University Health System Department of Clinical Education and Professional Development designates this activity for a maximum of 6.25 ACPE credit hours. Universal Activity Numbers: 0851-0000-17-100-L01-P.
- 6.25 ACPE - Pharmacist
- 6.25 AMA PRA Category 1 Credit(s)™
- 6.25 ANCC
- 6.25 Attendance